☰

Geoffrey W. Stone, Ph.D. - Publications

Affiliations: 
2000 University of British Columbia, Vancouver, Vancouver, BC, Canada 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Tian J, Ashique AM, Weeks S, Lan T, Yang H, Chen HH, Song C, Koyano K, Mondal K, Tsai D, Cheung I, Moshrefi M, Kekatpure A, Fan B, Li B, ... ... Stone GW, et al. ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms. Cancer Immunology Research. PMID 38393969 DOI: 10.1158/2326-6066.CIR-23-0568  0.34
2020 Pallikkuth S, Bolivar H, Fletcher MA, Babic DZ, De Armas LR, Gupta S, Termini JM, Arheart KL, Stevenson M, Tung FY, Fischl MA, Pahwa S, Stone GW. A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy. Vaccine. PMID 32387010 DOI: 10.1016/J.Vaccine.2020.04.015  0.527
2019 Hyun J, McMahon RS, Lang AL, Edwards JS, Badilla AD, Greene ME, Stone GW, Pallikkuth S, Stevenson M, Dykxhoorn DM, Kottilil S, Pahwa S, Thomas E. HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. Plos Pathogens. 15: e1007883. PMID 31260499 DOI: 10.1371/Journal.Ppat.1007883  0.397
2017 Termini JM, Gupta S, Raffa FN, Guirado E, Fischl MA, Niu L, Kanagavelu S, Stone GW. Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion. Plos One. 12: e0184915. PMID 28910387 DOI: 10.1371/Journal.Pone.0184915  0.39
2016 Gupta S, Termini JM, Issac B, Guirado E, Stone GW. Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors. Plos One. 11: e0148929. PMID 26849062 DOI: 10.1371/Journal.Pone.0148929  0.505
2016 Kornbluth RS, Gupta S, Termini JM, Guirado E, Stone GW. Abstract B062: Immune activation by LMP1 CD40 pathway and LMP1-IPS-1 STING pathway activators Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B062  0.519
2015 Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, Stevenson M, Pahwa S. Peripheral T Follicular Helper Cells Are the Major HIV Reservoir Within Central Memory CD4 T Cells in Peripheral Blood from chronic HIV infected individuals on cART. Journal of Virology. PMID 26676775 DOI: 10.1128/Jvi.02883-15  0.481
2015 Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 33: 4798-806. PMID 26241951 DOI: 10.1016/J.Vaccine.2015.07.081  0.476
2015 Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. Journal of Virology. 89: 4158-69. PMID 25631080 DOI: 10.1128/Jvi.02904-14  0.479
2014 Kanagavelu S, Termini JM, Gupta S, Raffa FN, Fuller KA, Rivas Y, Philip S, Kornbluth RS, Stone GW. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance t cell mediated anti-viral immunity Plos One. 9. PMID 24587225 DOI: 10.1371/Journal.Pone.0090100  0.472
2014 Gupta S, Termini JM, Raffa FN, Williams CA, Kornbluth RS, Stone GW. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag. Journal of Virology. 88: 1492-501. PMID 24227853 DOI: 10.1128/Jvi.02229-13  0.553
2014 Kornbluth R, Snarsky V, Stone G. Multimeric soluble 4-1BBL as a T cell stimulator for adoptive immunotherapy F1000research. 5. DOI: 10.7490/F1000Research.1097309.1  0.327
2014 Kornbluth RS, Snarsky V, Stone GW. Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy Journal For Immunotherapy of Cancer. 2: 246. DOI: 10.1186/2051-1426-2-S3-P246  0.441
2014 Daftarian PM, Ager AL, Stone G. A Targeted and Adjuvanted Nanoparticle for Immunochemotherapy of Leishmania Infections Current Tropical Medicine Reports. 1: 148-153. DOI: 10.1007/S40475-014-0023-X  0.324
2013 Gupta S, Termini JM, Kanagavelu S, Stone GW. Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics Immunologic Research. 57: 303-310. PMID 24198065 DOI: 10.1007/S12026-013-8443-6  0.535
2013 Daftarian PM, Stone GW, Kovalski L, Kumar M, Vosoughi A, Urbieta M, Blackwelder P, Dikici E, Serafini P, Duffort S, Boodoo R, Rodríguez-Cortés A, Lemmon V, Deo S, Alberola J, et al. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. The Journal of Infectious Diseases. 208: 1914-22. PMID 23901083 DOI: 10.1093/Infdis/Jit378  0.345
2012 Kornbluth RS, Stempniak M, Stone GW. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. International Reviews of Immunology. 31: 279-88. PMID 22804572 DOI: 10.3109/08830185.2012.703272  0.423
2012 Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine. 30: 691-702. PMID 22146759 DOI: 10.1016/J.Vaccine.2011.11.088  0.494
2012 Gupta S, Termini J, Stone G. Control of HIV replication by a novel constitutively active ‘super-PRR’ Retrovirology. 9: 306. DOI: 10.1186/1742-4690-9-S2-P306  0.473
2012 Termini J, Gupta S, Stone G. Evaluation of Latent Membrane Protein 1 as a novel vaccine adjuvant Retrovirology. 9: 11. DOI: 10.1186/1742-4690-9-S2-P11  0.419
2011 Gupta S, Termini JM, Niu L, Kanagavelu SK, Rahmberg AR, Kornbluth RS, Evans DT, Stone GW. Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines Retrovirology. 8. PMID 21592361 DOI: 10.1186/1742-4690-8-39  0.527
2011 Gupta S, Termini JM, Niu L, Kanagavelu SK, Schmidtmayerova H, Snarsky V, Kornbluth RS, Stone GW. Ebv LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine Journal of Leukocyte Biology. 90: 389-398. PMID 21586676 DOI: 10.1189/Jlb.0211068  0.555
2011 Niu L, Termini JM, Kanagavelu SK, Gupta S, Rolland MM, Kulkarni V, Pavlakis GN, Felber BK, Mullins JI, Fischl MA, Stone GW. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes Vaccine. 29: 2110-2119. PMID 21241732 DOI: 10.1016/J.Vaccine.2010.12.131  0.459
2009 Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, Zugates GT, Anderson DG, Kornbluth RS. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. Plos One. 4: e7334. PMID 19812695 DOI: 10.1371/Journal.Pone.0007334  0.393
2009 Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. Bmc Immunology. 10: 43. PMID 19650904 DOI: 10.1186/1471-2172-10-43  0.469
2009 Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine. 27: 5077-84. PMID 19573639 DOI: 10.1016/J.Vaccine.2009.06.046  0.569
2009 Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Kornbluth RS. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 802-8. PMID 19550243 DOI: 10.1097/Jto.0B013E3181A8634D  0.423
2009 Liu J, Ngai N, Stone G, Yue F, Ostrowski MA. P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine Retrovirology. 6: 11. DOI: 10.1186/1742-4690-6-S3-P11  0.489
2008 Liu J, Yu Q, Stone GW, Yue FY, Ngai N, Jones RB, Kornbluth RS, Ostrowski MA. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine. 26: 4062-72. PMID 18562053 DOI: 10.1016/J.Vaccine.2008.05.018  0.538
2006 Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, Pillai VK, Amara RR, Villinger F, Kornbluth RS. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clinical and Vaccine Immunology : Cvi. 13: 1223-30. PMID 16988005 DOI: 10.1128/Cvi.00198-06  0.537
2006 Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. Journal of Leukocyte Biology. 80: 1084-102. PMID 16931603 DOI: 10.1189/Jlb.0306147  0.554
2006 Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, Kornbluth RS. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. Journal of Virology. 80: 1762-72. PMID 16439533 DOI: 10.1128/Jvi.80.4.1762-1772.2006  0.553
2006 Stone G, Barzee S, Snarsky V, Toppin C, Tran B, Kornbluth R. OR.95. Anti‐Tumor Effects of Combined CD40 and TLR Stimulation: Tumor-Specific Requirements for the Treatment of Established Tumors Clinical Immunology. 119. DOI: 10.1016/J.Clim.2006.04.400  0.334
Show low-probability matches.